Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety.
Duszynski KM, Stark JH, Cohet C, Huang WT, Shin JY, Lai EC, Man KKC, Choi NK, Khromava A, Kimura T, Huang K, Watcharathanakij S, Kochhar S, Chen RT, Pratt NL. Duszynski KM, et al. Among authors: chen rt. Pharmacoepidemiol Drug Saf. 2021 Jul;30(7):843-857. doi: 10.1002/pds.5214. Epub 2021 Mar 23. Pharmacoepidemiol Drug Saf. 2021. PMID: 33634545
Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services.
Top KA, Chen RT, Levy O, Ozonoff A, Carleton B, Crawford NW, Creech CB, Kochhar S, Poland GA, Gutu K, Cutland CL. Top KA, et al. Among authors: chen rt. Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S11-S17. doi: 10.1093/cid/ciac407. Clin Infect Dis. 2022. PMID: 35680552 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).
Leav B, Straus W, White P, Leav A, Gaines T, Maggiacomo G, Kim D, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO ex-V3SWG. Leav B, et al. Among authors: chen rt. Vaccine. 2022 Aug 19;40(35):5275-5293. doi: 10.1016/j.vaccine.2022.06.005. Epub 2022 Jun 9. Vaccine. 2022. PMID: 35753841 Free PMC article.
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.
Hernandez LM, Sumathy K, Sahastrabuddhe S, Excler JL, Kochhar S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO, ex-V3SWG). Hernandez LM, et al. Among authors: chen rt. Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM, Jenkin D, Morris S, Gilbert S, Kim D, Robertson JS, Smith ER, Martin E, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group BRAVATO, ex-V3SWG). Folegatti PM, et al. Among authors: chen rt. Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14. Vaccine. 2022. PMID: 35715352 Free PMC article.
367 results